Lajos Pusztai
D.Phil.
The University of Texas
MD Anderson Cancer Center
Department of Breast Medical Oncology
USA
Name/email consistency: high
- Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX(R)) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer. Kelly, C.M., Bernard, P.S., Krishnamurthy, S., Wang, B., Ebbert, M.T., Bastien, R.R., Boucher, K.M., Young, E., Iwamoto, T., Pusztai, L. Oncologist (2012)
- Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Iwamoto, T., Booser, D., Valero, V., Murray, J.L., Koenig, K., Esteva, F.J., Ueno, N.T., Zhang, J., Shi, W., Qi, Y., Matsuoka, J., Yang, E.J., Hortobagyi, G.N., Hatzis, C., Symmans, W.F., Pusztai, L. J. Clin. Oncol. (2012)
- The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Lacerda, L., Pusztai, L., Woodward, W.A. Drug Resist. Updat. (2010)
- Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Pusztai, L., Jeong, J.H., Gong, Y., Ross, J.S., Kim, C., Paik, S., Rouzier, R., Andre, F., Hortobagyi, G.N., Wolmark, N., Symmans, W.F. J. Clin. Oncol. (2009)
- Gene expression profiling of breast cancer. Pusztai, L. Breast Cancer Res. (2009)
- Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. Pusztai, L., Broglio, K., Andre, F., Symmans, W.F., Hess, K.R., Hortobagyi, G.N. J. Clin. Oncol. (2008)
- Current status of prognostic profiling in breast cancer. Pusztai, L. Oncologist (2008)
- Preoperative systemic chemotherapy and pathologic assessment of response. Pusztai, L. Pathol. Oncol. Res. (2008)
- Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Pusztai, L. Ann. Oncol. (2007)
- New generation of molecular prognostic and predictive tests for breast cancer. Pusztai, L., Cristofanilli, M., Paik, S. Semin. Oncol. (2007)
- Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Pusztai, L., Anderson, K., Hess, K.R. Clin. Cancer Res. (2007)
- Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pusztai, L. Pharmacogenomics (2007)
- Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Pusztai, L., Esteva, F.J. Cancer Invest. (2006)
- Molecular classification of breast cancer: limitations and potential. Pusztai, L., Mazouni, C., Anderson, K., Wu, Y., Symmans, W.F. Oncologist (2006)
- Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer. Pusztai, L. Adv. Exp. Med. Biol. (2006)
- Chips to bedside: incorporation of microarray data into clinical practice. Pusztai, L. Clin. Cancer Res. (2006)
- Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 2005, San Diego, CA, USA. Pusztai, L. IDrugs (2005)
- Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Pusztai, L., Symmans, F.W., Hortobagyi, G.N. Breast. Cancer (2005)
- Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F.W., Wong, F., Blumenschein, G., Fleming, D.R., Rouzier, R., Boniface, G., Hortobagyi, G.N. Cancer (2005)
- Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., Syed, A., Fritsche, H.A., Bruera, E., Booser, D., Valero, V., Arun, B., Ibrahim, N., Rivera, E., Royce, M., Cleeland, C.S., Hortobagyi, G.N. Cytokine (2004)
- Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Pusztai, L., Gregory, B.W., Baggerly, K.A., Peng, B., Koomen, J., Kuerer, H.M., Esteva, F.J., Symmans, W.F., Wagner, P., Hortobagyi, G.N., Laronga, C., Semmes, O.J., Wright, G.L., Drake, R.R., Vlahou, A. Cancer (2004)
- Clinical trial design for microarray predictive marker discovery and assessment. Pusztai, L., Hess, K.R. Ann. Oncol. (2004)
- Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. Pusztai, L., Rouzier, R., Wagner, P., Symmans, W.F. Drug Resist. Updat. (2004)
- Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. Pusztai, L., Gianni, L. Nature Clinical Practice. Oncology (2004)
- Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Pusztai, L., Sotiriou, C., Buchholz, T.A., Meric, F., Symmans, W.F., Esteva, F.J., Sahin, A., Liu, E.T., Hortobagi, G.N. Cancer Genet. Cytogenet. (2003)
- Clinical application of cDNA microarrays in oncology. Pusztai, L., Ayers, M., Stec, J., Hortobágyi, G.N. Oncologist (2003)
- Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Pusztai, L., Ayers, M., Stec, J., Clark, E., Hess, K., Stivers, D., Damokosh, A., Sneige, N., Buchholz, T.A., Esteva, F.J., Arun, B., Cristofanilli, M., Booser, D., Rosales, M., Valero, V., Adams, C., Hortobagyi, G.N., Symmans, W.F. Clin. Cancer Res. (2003)
- Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. Pusztai, L., Zhen, J.H., Arun, B., Rivera, E., Whitehead, C., Thompson, W.J., Nealy, K.M., Gibbs, A., Symmans, W.F., Esteva, F.J., Booser, D., Murray, J.L., Valero, V., Smith, T.L., Hortobagyi, G.N. J. Clin. Oncol. (2003)
